Banner Slide

Going further to bring better todays to even more people with cancer

Building better todays for more patients worldwide

At Helsinn, we’ve made it our mission to improve the everyday lives of patients. We’ve been a family-run pharmaceutical company since we were founded over 40 years ago, guided by our values of integrity, respect and with a 360-degree approach to quality that runs through everything we do. Today, we’re leading the way in supportive care in cancer, and are committed to building better todays for more patients worldwide.

Our Business

The Helsinn Group is one of the world's leading supportive cancer care companies, with a comprehensive portfolio of medicines and therapies helping to improve the lives of patients in countries around the world.

Learn more

Corporate Social Responsibility and Sustainability

Sustainability is becoming an increasingly central part of Helsinn’s culture and business strategy. Integrity, quality and respect have always been at the core of our business, but increasingly, organisations are aware that they function as part of an ecosystem to which they have a responsibility. Care for the communities in which we operate, and stewardship of our environment, are as important to our long-term future as the economic bottom line.

Learn more

Our Products

The strength of the Helsinn model is reflected in the product candidates that we have transformed into sustainable market successes.

Learn more

Our Building Blocks

News & Events

Helsinn Announces Attendance at the CPhI 2017 Conference in Frankfurt

Helsinn will be attending between 24-26 October at Booth Number 61B20, Hall 6.1 on the Integrated Pharma Gold corridor H...

Read more

Helsinn Pharmaceuticals (Beijing) Co. Ltd. Opens Office in Shanghai, China

Helsinn Pharmaceuticals (Beijing) Co. Ltd., Shanghai branch, was approved on August 7, 2017 by the Shanghai Administrati...

Read more

Helsinn Group supports prIME’s Satellite Symposium at ESMO 2017

World-renowned supportive care experts in oncology explore how to provide the best care for patients by incorporating pa...

Read more

Helsinn Group Announces Upcoming Presentation of Phase III data of NEPA (fosnetu...

Preliminary findings demonstrate intravenous NEPA to be safe and well-tolerated, with a similar safety profile to oral N...

Read more

Helsinn Therapeutics (U.S.) Inc., Signs Co-Promotion Agreement for Cancer Therap...

Zykadia® (ceritinib) is an approved treatment for patients with metastatic non-small cell lung cancer (NSCLC) whose tumo...

Read more